(Lung Cancer) Efficacy of Lorlatinib?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- January 10, 2020
- Reading time: 2 minutes
On October 25, 2019, Alice T. Shaw published results in The Lancet Oncology from a Phase 1/2 clinical trial evaluating the efficacy and safety of lorlatinib — a third-generation ALK tyrosine kinase inhibitor — as monotherapy in ROS1-positive non-small cell lung cancer (NSCLC) patients.
This Phase 1/2 trial was a single-arm, open-label study. Patients with ROS1-positive NSCLC received lorlatinib 100 mg once daily. The primary endpoint was objective response rate (ORR); secondary endpoint was safety.
Efficacy Results:
ORR by prior treatment history:
- Previously treated, TKI-naive patients: 62% (N=21)
- Previously treated with crizotinib: 35% (N=40)
Intracranial response rate:
- Previously treated, TKI-naive patients: 64% (N=11)
- Previously treated with crizotinib: 50% (N=24)
Safety:
The most common Grade 3–4 adverse events were hypertriglyceridemia (19%) and hypercholesterolemia (14%). Although 5 of 69 patients experienced more severe adverse events, no treatment-related deaths were reported.
Based on the Phase 1/2 trial results, Alice T. Shaw concluded that lorlatinib monotherapy demonstrated favorable antitumor activity in ROS1-positive NSCLC patients, including those with brain metastases and those previously treated with crizotinib.
Source: Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial (Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30655-2. doi: 10.1016/S1470-2045(19)30655-2.)
#LungCancer #Lorlatinib
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4